Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-Hodgkin lymphoma
Research
Innate antibody pits NK cells against lymphoma in animal models
The antibody, called IPH6501, is now being evaluated in a phase 1/2 trial in patients with relapsed or unresponsive B cell non-Hodgkin lymphoma.
Darren Incorvaia
Nov 15, 2024 2:00pm
Merck pays $700M for bispecific challenger to Amgen cancer drug
Aug 9, 2024 8:52am
ASH: AZ spinout Dizal explores FDA path, US partner for PTCL med
Dec 11, 2023 4:30am
C4 culls phase 1/2 cancer program after efficacy fail
Nov 1, 2023 11:29am
Soligenix shares take another dip as FDA requests 2nd trial
Apr 14, 2023 11:02am
ASH: Should existing BTKs worry about Lilly's newcomer?
Dec 12, 2022 5:30pm
